Phase 1 trial of third-generation anti-CD19 CAR T-cell therapy for patients with cancer
Phase of Trial: Phase I
Latest Information Update: 01 May 2017
At a glance
- Drugs Anti-CD19 CAR-transduced T cells (Primary)
- Indications B cell lymphoma; Leukaemia; Multiple myeloma
- Focus Adverse reactions
- 01 May 2017 According to a ZIOPHARM Oncology media release, the company plans to initiate this study in second half 2017.
- 02 Mar 2017 New trial record
- 31 Jan 2017 According to a ZIOPHARM Oncology media release, this trial is expected to start in late 2017.